Research location

Changsha

Hunan, China

Published trials848

Site observations1,080

Linked trials published848

Page2 / 17

Research activity in Changsha

Hunan, China

CureCurrent currently publishes aggregate city-level research activity for this location: 848 trials and 1,080 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Changsha

848 linked trials · page 2 of 17

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C MutationNCT07174908 · 2025-09-10 · 1 site observation

The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer PatientsNCT07138755 · 2025-08-29 · 2 site observations

A Study of SKB518 in Patients With Lung CancerNCT07019675 · 2025-08-29 · 1 site observation

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499 · 2025-08-20 · 1 site observation

Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2NCT07097818 · 2025-08-18 · 1 site observation

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.NCT07062965 · 2025-08-05 · 1 site observation

A Study of YL202 in Patients With Advanced Solid TumorsNCT07202364 · 2025-08-04 · 1 site observation

Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung CancerNCT07061535 · 2025-07-30 · 1 site observation

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)NCT07079475 · 2025-07-30 · 1 site observation

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerNCT07047365 · 2025-07-25 · 3 site observations

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 · 2025-07-25 · 1 site observation

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast CancerNCT07024173 · 2025-07-23 · 1 site observation

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.NCT06758401 · 2025-07-23 · 1 site observation

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)NCT07060807 · 2025-07-21 · 1 site observation

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid TumorsNCT06953089 · 2025-07-18 · 1 site observation

A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT07292714 · 2025-07-15 · 1 site observation

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)NCT07011732 · 2025-07-10 · 1 site observation

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast CancerNCT07008976 · 2025-07-07 · 1 site observation

Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia PatientsNCT07045142 · 2025-07-01 · 2 site observations

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30 · 2 site observations

Hybrid Closed-Loop for Perioperative Glycemic Control in T2DM With Parenteral NutritionNCT07121504 · 2025-06-26 · 1 site observation

Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical TrialNCT07103382 · 2025-06-26 · 1 site observation

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 · 2025-06-25 · 3 site observations

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast CancerNCT07003074 · 2025-06-23 · 1 site observation

Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung CancerNCT06926140 · 2025-06-21 · 1 site observation

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 InflammationNCT06959095 · 2025-06-20 · 1 site observation

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)NCT06991257 · 2025-06-19 · 1 site observation

The Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast ReconstructionNCT06995118 · 2025-06-17 · 1 site observation

A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation TherapyNCT07010263 · 2025-06-13 · 2 site observations

A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerNCT06891833 · 2025-06-05 · 2 site observations

Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic AirspacesNCT07066813 · 2025-06-01 · 1 site observation

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · 2025-05-22 · 2 site observations

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast CancerNCT06957886 · 2025-05-15 · 1 site observation

A Study of DXC008 in Patients With Prostate Cancer and Other Solid TumorsNCT06926283 · 2025-05-15 · 1 site observation

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)NCT06925737 · 2025-05-13 · 1 site observation

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerNCT06892548 · 2025-05-02 · 1 site observation

Multimodal AI Predicts High-risk Pathology in Lung Cancer Associated With Cystic AirspacesNCT07820423 · 2025-05-01 · 1 site observation

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)NCT06875310 · 2025-04-24 · 1 site observation

Establishment of a Classification System and Postoperative Risk Warning Model for Patients Undergoing Bariatric Metabolic Surgery for Severe ObesityNCT07093502 · 2025-04-01 · 1 site observation

TQC2731 Clinical Trial for the Treatment of Severe Asthma With InjectionNCT06829784 · 2025-03-21 · 3 site observations

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)NCT06841354 · 2025-03-16 · 1 site observation

Development and Application of Accurate Detection Technology Based on Multimodal Data of Breast Cancer Comobid DepressionNCT06938373 · 2025-03-11 · 1 site observation

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623 · 2025-03-06 · 1 site observation

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514 · 2025-02-27 · 1 site observation

A Phase I Study of SIM0505 in Participants With Advanced Solid TumorsNCT06792552 · 2025-02-26 · 1 site observation

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).NCT06646276 · 2025-02-25 · 1 site observation

Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung CancerNCT06840704 · 2025-02-25 · 3 site observations

Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast CancerNCT06889688 · 2025-02-21 · 1 site observation

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced MalignanciesNCT06839105 · 2025-02-21 · 1 site observation

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLCNCT06864624 · 2025-02-18 · 1 site observation

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.